Purpose: Spontaneously ruptured hepatocellular carcinoma (srHCC) is known to be a life-threatening complication with poor prognosis. Although there are various treatment modalities, there is no definite treatment guideline. The purpose of this study was to review the surgical outcome and prognosis of srHCC treated with intraoperative radiofrequency ablation (RFA) and distilled water peritoneal lavage (DWPL).
Methods: From March 2012 to October 2018, 9 patients with srHCC who underwent emergent surgery were reviewed. After hematoma removal, intraoperative RFA and DWPL were applied to all patients. Hepatectomy was performed if necessary. Patients with multiple tumors, distant metastasis, and vascular tumor involvement in radiologic imaging were excluded.
Results: Six of 9 patients with diameters less than 7 cm were able to obtain hemostasis using RFA alone (RFA group). However, 3 patients with a tumor size of more than 10 cm underwent liver resection because they could not obtain hemostasis with RFA (hepatectomy only group). The RFA group had shorter operation time (148.3 ± 31.7 minutes 251.7 ± 20.2 minutes, P < 0.05) and less red blood cell transfusion (5.8 ± 2.5 packs 24.0 ± 11.5 packs, P < 0.05) than the hepatectomy only group. There was no peritoneal metastasis at long-term follow-up in the RFA group. Five-year recurrence-free survival rate was 0% in both groups. However, 5-year overall survival rate was better in the RFA group (83.3% 0%, P < 0.05).
Conclusion: Intraoperative RFA and DWPL are easy to perform and theoretically the best methods for managing relatively small srHCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893220 | PMC |
http://dx.doi.org/10.4174/astr.2019.97.6.291 | DOI Listing |
ANZ J Surg
December 2024
Department of Oncology, Leping Traditional Chinese Medicine Hospital, Leping, China.
Background: Both radiofrequency ablation (RFA) and microwave ablation (MWA) are commonly used non-surgical treatment methods for lung cancer/lung metastases (LC/LM). However, there is still debate over which one is superior. The meta-analysis was conducted to evaluate the effectiveness and safety between the two groups.
View Article and Find Full Text PDFAnn Ital Chir
December 2024
Radiotherapy Department, Affiliated Hospital of Hebei University, 071003 Baoding, Hebei, China.
Open Life Sci
December 2024
School infirmary, Fudan University, Shanghai, 200433, China.
Both irreversible electroporation (IRE) and radiofrequency ablation (RFA) are viable ablation methods for localized treatment of liver tumors. We conducted a meta-analysis to access the efficacy and safety of IRE and RFA in liver cancer treatment. Clinical studies on IRE and RFA for the treatment of liver cancer were collected from PubMed and CNKI until June 2023.
View Article and Find Full Text PDFJACC Clin Electrophysiol
November 2024
Arrhythmia and Robotic EP Unit, Cardiology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address:
Background: The optimal radiofrequency application (RFa) parameters for safe and durable pulmonary vein isolation (PVI) are debated. High-power short-duration (HPSD) has been used as an alternative to conventional power delivery (CPD).
Objectives: This study sought to compare HPSD 70 W/9-10 s (HPSD-70) with CPD 25-40 W in patients undergoing PVI.
J Cardiothorac Surg
December 2024
Department of Cardiovascular Medicine, Deyang People's Hospital, No. 173, Section 1, Taishan North Road, Jingyang District, Deyang, Sichuan Province, 618000, China.
Background: Paroxysmal atrial fibrillation (PAF) usually recurs after radiofrequency ablation (RFA). This study probed the predictive value of monocyte count to high-density lipoprotein cholesterol (HDL-C) ratio (MHR) with left atrial diameter (LAD) for post-RFA recurrence in PFA patients.
Methods: Totally 210 RFA-treated PAF patients were selected and assigned into Recurrence and Non-Recurrence groups, with clinical baseline data recorded.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!